Whole Genome Sequencing for Blood Group Genotyping and Definition as Exemplified on U- and St(a)+.

Overview

No health condition(s) are studied. Genetic background of blood groups is studied. U- and Stones(a)+ ("Caucasian type") are used as proof-of-principle samples. Disease associations of all blood group genes investigated are very rare, e.g. < 1 among 1'000 Swiss individuals (see table 1), and are not to be expected in the course of this study. Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent.

Full Title of Study: “Applicability of Whole Genome Sequencing for Human Blood Group Genotyping and Genetic Definition of New Alleles as Exemplified on References and the Two MNSs-variants: U- and Stones(a)+”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
  • Study Primary Completion Date: June 2016

Detailed Description

All 34 human blood group systems have at least two antithetical antigens and are of potential relevance during pregnancy and transfusion. Fortunately for every day routine practice, immunizations to foreign antigens are rare. Still, incompatibilities may occur in all blood group systems and will then require typing for the respective blood group antigens. Blood genotyping evolved as the method of choice, in cases when typing reagents are commercially unavailable, or blood is inaccessible (foetus). In databases, most entries of blood group genes lack representative polymorphism (e.g. number of alleles). Moreover, many blood group antigens are insufficiently described in their intronic and inter-genetic sequences. This is true for results of unequal crossing-overs, gene-conversions and large insertions/deletions between highly homologous genes, especially within the blood group systems of Rhesus, e.g. RhD/RhCE and MN/Ss, respectively. Only Whole Genome Sequencing (WGS) allows for resolution of both problems: it delivers the whole blood group genome of an individual, and simultaneously recognizes new blood group alleles, or haplotypes. This request for ethical approval wants to test this assumption. The antigenic determinants U- and Stones(a)+ of the blood group system MNSs still lack full genetic description and will serve as challenging examples for the description of new alleles (haplotypes) caused by large ins/del mutations of the two highly homologous genes GYPA and B. Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent. Additional reference samples (n max=4), and samples with suspected Stones(a)+ (n max=4) will be recruited from Zurich blood donors with informed consent, only.

Interventions

  • Other: Whole Genome Sequencing (WGS)
    • There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.

Arms, Groups and Cohorts

  • people negative in bg MNSs antigen U
    • Blood group (bg) system MNSs. Individuals with phenotype “U-“. Homo- and heterozygous individuals may be considered.
  • people positive in bg MNSs antigen St(a)
    • Blood group (bg) system MNSs. Individuals with phenotype “St(a)+”. Homo- and heterozygous individuals may be considered.

Clinical Trial Outcome Measures

Primary Measures

  • Whole Genome Sequencing for the definition of genetic background for blood group antigens U-, St(a)+
    • Time Frame: 2 year period
    • During a 2 year time-period, whole genome sequencing data generation and analysis will be used for the analysis and description of the genetic background for the blood group antigens U negativity, and for St(a).

Participating in This Clinical Trial

Inclusion Criteria

  • Existing biomaterial (gDNA), or – Existing health related data for blood group U- (n max=2) and eligible for (venous) blood sampling of 20 mL, or – Existing blood group pheno- and genotyping data indicating St(a)+ and eligible for (venous) blood sampling of 20 mL (n max=2), or – Adequate blood group profile serving as reference (n max =4 & n max =4'000) and eligible for (venous) blood sampling of 20 mL. Exclusion Criteria:

  • Ineligible for venous blood sampling of approx. 20 mL.

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Blood Donation Service Zurich, SRC
  • Provider of Information About this Clinical Study
    • Principal Investigator: Christoph Gassner, Priv. Doz. Mag. Dr. rer. nat. Christoph Gassner – Blood Donation Service Zurich, SRC
  • Overall Official(s)
    • Christoph Gassner, PhD, Principal Investigator, Blutspende Zürich, Dienstleistungszentrum
  • Overall Contact(s)
    • Christoph Gassner, PhD, +41 58 272 5195, c.gassner@zhbsd.ch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.